- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Chen Explores Possible Genomic Basis for Racial Disparities in CTCL Outcomes
Pei-Ling Chen, MD, PhD, discusses genomic findings that may explain poorer outcomes for Black patients with CTCL.
- 2x
- 1.75x
- 1.5x
- 1.25x
- 1x, selected
- 0.75x
- 0.5x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Pei-Ling Chen, MD, PhD, is a member of the Pathology and Cutaneous Oncology Departments at Moffitt Cancer Center and a member of the Moffitt Cutaneous Lymphoma Multidisciplinary Clinic specializing in the research and treatment of cutaneous T-cell lymphoma (CTCL).
Dr. Chen recently published results of a multiomics profiling of 56 patients with transformed CTCL that may represent the first time investigators have identified a potential genomic cause for poorer outcomes for Black patients with CTCL.
Investigators determined that, compared with White patients, Black patients showed a reduced UV signature and enrichment of a unique signature cluster with DNA mismatch repair. Chen and her collegues speculate that these factors drive the race-based disparity in outomes in CTCL.
Related Content:
